RNA assays up sensitivity of urothelial carcinoma detection

August 21, 2012
RNA assays up sensitivity of urothelial carcinoma detection
Cxbladder, a derivative of the RNA assay uRNA, may be an effective alternative to cytology and nuclear matrix protein 22 assays for the detection of urothelial carcinoma, according to a study published in the September issue of The Journal of Urology.

(HealthDay) -- Cxbladder, a derivative of the RNA assay uRNA, may be an effective alternative to cytology and nuclear matrix protein 22 (NMP22) assays for the detection of urothelial carcinoma, according to a study published in the September issue of The Journal of Urology.

To compare the sensitivity and specificity of the RNA tests with cytology and NMP22 assays (NMP22 BladderChek and NMP22 enzyme-linked immunosorbent assay [ELISA]) using cystoscopy as the reference, Paul O'Sullivan, M.D., of Pacific Edge Ltd. in Dunedin, New Zealand, and associates conducted a prospective study of 485 patients presenting with gross hematuria with no history of urothelial cancer.

Of 66 patients with , the researchers found that uRNA detected 62.1 percent of the cases, compared with cytology (56.1 percent), NMP22 ELISA (50 percent), and BladderChek (37.9 percent). Cxbladder detected 82 percent of cases, including 100 percent of tumors stage 1 or greater and 97 percent of high-grade tumors. The specificity of Cxbladder and uRNA were prespecified at 85 percent, and the specificity of , NMP22 ELISA, and BladderChek were 94.5, 88.0, and 96.4 percent, respectively. Cxbladder was able to differentiate between low-grade Ta tumors and other detected urothelial carcinoma with a sensitivity and a specificity of 91 and 90 percent, respectively.

"uRNA and Cxbladder showed improved sensitivity for the detection of urothelial carcinoma compared to the NMP22 assays," the authors write. "Stratification with Cxbladder provides a potential method to prioritize patients for the management of waiting lists."

Several authors disclosed (including employment) to Pacific Edge Ltd., which manufactures Cxbladder.

Explore further: Combination HPV diagnostic test for head and neck cancer outperformed other tests

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

PET more sensitive than CT for merkel cell carcinoma

May 15, 2012

(HealthDay) -- Fluorine-18-fluorodeoxyglucose (F-18-FDG) positron emission tomography (PET) is significantly more sensitive and equally specific compared with traditional computed tomography (CT) imaging for evaluation of ...

Recommended for you

Dogs detect breast cancer from bandage: researchers

March 24, 2017

Dogs can sniff out cancer from a piece of cloth which had touched the breast of a woman with a tumour, researchers said Friday, announcing the results of an unusual, but promising, diagnostic trial.

'Jumonji' protein key to Ewing's sarcoma rampage

March 24, 2017

By the time Ewing's Sarcoma is diagnosed, primarily in teens and young adults, it has often spread from its primary site to other parts of the body, making it difficult to treat. A University of Colorado Cancer Center study ...

In a sample of blood, researchers probe for cancer clues

March 24, 2017

One day, patients may be able to monitor their body's response to cancer therapy just by having their blood drawn. A new study, led by bioengineers at UC Berkeley, has taken an important step in that direction by measuring ...

Researchers gain insight into breast cancer drug resistance

March 24, 2017

Breast cancer's ability to develop resistance to treatment has frustrated researchers and physicians and has thwarted even the latest and greatest targeted therapies. For example, after researchers identified a disease pathway ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.